Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

HER2DX: a new diagnostic tool for early-stage HER2 positive breast cancer

BGICC 2023

19 - 20 Jan 2023

Published: 7 Feb 2023

Views: 103

Rating:

Save

Prof Aleix Prat - Hospital Clínic Barcelona, Barcelona, Spain

Prof Prof Aleix Prat speaks to ecancer about his talk at BGICC 2023 on HER2DX: a new diagnostic tool for early-stage HER2 positive breast cancer.

He explains that HER2DX is a new assay that is the result of 10 years of research in early-stage HER2 positive breast cancer.

Prof Prat then outlines the three types of information that HER2DX can provide for oncologists.

Related Videos

SOFT study: Clinical relevance of genomic alterations in premenopausal HR+...

Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia

SOFT study: Clinical relevance of genomic alterations in premenopausal HR+, HER2- early breast cancer ( Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia )

IORT at the Asian Hospital and Medical Center

Dr Aldine Basa - Asian Hospital and Medical Center, Manila, Philippines

IORT at the Asian Hospital and Medical Center ( Dr Aldine Basa - Asian Hospital and Medical Center, Manila, Philippines )

The TARGIT-A randomised trial: TARGIT-IORT versus whole breast radiation...

Dr Jayant Vaidya - University College London, London, UK

The TARGIT-A randomised trial: TARGIT-IORT versus whole breast radiation therapy: long-term local control and survival ( Dr Jayant Vaidya - University College London, London, UK )

Insights from TARGIT-A trial of targeted IORT during lumpectomy for breast...

Dr Jayant Vaidya - University College London, London, UK

Insights from TARGIT-A trial of targeted IORT during lumpectomy for breast cancer ( Dr Jayant Vaidya - University College London, London, UK )

Moving to the future: Artificial intelligence in surgery

Dr Maria João Cardoso - Champalimaud Cancer Centre, Lisbon, Portugal

Moving to the future: Artificial intelligence in surgery ( Dr Maria João Cardoso - Champalimaud Cancer Centre, Lisbon, Portugal )

An overview of treatment advances in gastric cancer

Prof David Ilson - Memorial Sloan Kettering Cancer Center, New York City, USA

An overview of treatment advances in gastric cancer ( Prof David Ilson - Memorial Sloan Kettering Cancer Center, New York City, USA )

Locally and advanced immunotherapy developments and new agents in lung cancer

Dr George Simon - Moffitt Advent Health Clinical Research Unit, Tampa, USA

Locally and advanced immunotherapy developments and new agents in lung cancer ( Dr George Simon - Moffitt Advent Health Clinical Research Unit, Tampa, USA )

Comment: LUMINA results show that women with low levels of the Ki67 biomarker...

Dr Corey Wayne Speers - University of Michigan, Ann Arbor, USA

Comment: LUMINA results show that women with low levels of the Ki67 biomarker can avoid outcomes related to radiotherapy ( Dr Corey Wayne Speers - University of Michigan, Ann Arbor, USA )

Biomarker guidance allows patients 55 or older with low-grade luminal A-type...

Dr Timothy J. Whelan - McMaster University, Ontario, Canada

Biomarker guidance allows patients 55 or older with low-grade luminal A-type breast cancer to avoid radiation therapy ( Dr Timothy J. Whelan - McMaster University, Ontario, Canada )

More from ecancer